Anke Schmidt (55) has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who has headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities. Anke Schmidt will report directly to the CEO of Fresenius, Michael Sen.

“With Anke Schmidt we have won an internationally experienced and highly recognized communications expert for Fresenius. With her many years of experience at DAX 40 companies, she will further strengthen our positioning as a leading global healthcare company and continue to build our brand, while also driving the strategic development of the communications function. Especially in this current phase of #FutureFresenius, Rejuvenate, it is about setting new impulses to shape an innovative, relevant, and sustainably successful Fresenius,” says Michael Sen, CEO of Fresenius. “Dennis Hofmann has reorganized and strengthened the global communications function at Fresenius in recent years. Under his leadership, the communications team played a decisive role in positioning Fresenius in the initial phase of its transformation. I would like to sincerely thank him for his great work and commitment and to wish him all the best for his future endeavors.”

Before joining Fresenius, Anke Schmidt served as Global Vice President Corporate Communications & Government Relations at Beiersdorf from 2020 onwards. Prior to that, she spent 24 years in various senior roles in Communications, Government Relations, and Human Resources at BASF, both in Germany and abroad. From 2016 to 2020, she was responsible for BASF Group’s Corporate Communications & Government Relations. Anke Schmidt studied French, economics, and political science at the University of Hamburg and the Université de Nantes in France.

# # #

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com.
Visit our media center: www.fresenius.com/media-center

Fresenius announced today that the internationally experienced and highly recognized communications expert Anke Schmidt has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities.

Anke Schmidt joins Fresenius from Beiersdorf, where she has served as Global Vice President Corporate Communications & Government Relations since 2020. Prior to that, she held various senior roles in Communications, Government Relations, and Human Resources at BASF over a period of 24 years, both in Germany and abroad.
 

Fresenius announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for its denosumab biosimilar candidates for the treatment of osteoporosis and other bone-related conditions.

The biosimilars are recommended for approval for all indications of the reference products ¹Prolia® (denosumab) and ²Xgeva® (denosumab) from AMGEN.

The CHMP positive opinion marks an important step in Fresenius Kabi's efforts to enhance patient access to biosimilar products and expand its capabilities and portfolio in biosimilars development. Developing the company's Biopharma platform is a key element of #FutureFresenius.

¹Prolia® and ²Xgeva® are registered trademarks of Amgen Inc.

Fresenius announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for its denosumab biosimilar candidates for the treatment of osteoporosis and other bone-related conditions.

The biosimilars are recommended for approval for all indications of the reference products ¹Prolia® (denosumab) and ²Xgeva® (denosumab) from AMGEN.

The CHMP positive opinion marks an important step in Fresenius Kabi's efforts to enhance patient access to biosimilar products and expand its capabilities and portfolio in biosimilars development. Developing the company's Biopharma platform is a key element of #FutureFresenius.

¹Prolia® and ²Xgeva® are registered trademarks of Amgen Inc.

 

• Management Board and Supervisory Board approved by a large majority
• Dividend of 1.00 euro per share agreed
• Wolfgang Kirsch re-elected as Chairman of the Supervisory Board

At today’s Annual General Meeting (AGM) in Frankfurt am Main, Germany, the shareholders of Fresenius SE & Co. KGaA approved the proposals of the General Partner and the Supervisory Board with a large majority.

The actions of the General Partner and the Supervisory Board in 2024 were approved by 99.66 percent and 97.36 percent respectively. 99.98 percent voted in favor of approving the annual financial statements. 95.83 percent of the shareholders approved the compensation report for the 2024 financial year and 99.37 percent approved the dividend proposal of 1.00 euro per share. The resolutions on the remuneration for the members of the Supervisory Board and extending the authorization to hold virtual annual general meetings were also adopted with large majorities. 77.93 percent of the share capital was represented at the AGM.

Following the AGM, the newly appointed Supervisory Board of Fresenius SE & Co. KGaA re-elected Wolfgang Kirsch as its chair during its constituent meeting. Michael Diekmann and Grit Genster were also confirmed as deputy chairs and Susanne Zeidler was confirmed as chair of the Audit Committee. The shareholders previously re-elected Prof. Dr. Iris Löw-Friedrich and Dr. Christoph Zindel to the Supervisory Board in addition to Kirsch, Diekmann, and Zeidler. After 14 years in office, Prof. Dr. med. D. Michael Albrecht stepped down from the Supervisory Board. The AGM elected Prof. Dr. Ralf Kiesslich, Chairman of the Board of the University Medical Centre in Mainz, as his successor. The six employee representatives had already been elected beforehand. All Supervisory Board members were appointed for the period until the end of the 2029 AGM.

The new Supervisory Board of Fresenius SE & Co. KGaA comprises the following members:

Wolfgang Kirsch (Chairman)
Michael Diekmann (Deputy Chair)
Grit Genster (Deputy Chair)
Bernd Behlert
Tania Lara Campaña
Carsten Georg
Prof. Dr. Ralf Kiesslich
Prof. Dr. Iris Löw-Friedrich
Holger Michel
Oscar Romero de Paco
Susanne Zeidler
Dr. Christoph Zindel

* * *

About Fresenius

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com
Follow us on social media: www.fresenius.com/socialmedia

• The disciplined implementation of #FutureFresenius has made Fresenius a simpler, more focused, and stronger company.
• With the next phase, Rejuvenate, the focus in the years ahead will be on strengthening the core businesses, scaling platforms, and elevating performance.
• Dividend of 1.00 euro per share proposed.

Thanks to the successful ongoing implementation of its #FutureFresenius strategy, Fresenius considers itself well-positioned to continue to deliver profitable growth and create long-term value. “With #FutureFresenius, the company has a coherent strategy that it will continue to implement consistently and successfully in the interests of all stakeholders. The Supervisory Board firmly believes that Fresenius fulfils all the requirements needed to achieve its ambitious goals. We support the course that the Management Board is pursuing. On behalf of the Supervisory Board, I thank the Management Board and all employees for their outstanding work,” said Wolfgang Kirsch, Chairman of the Supervisory Board, at this year’s Annual General Meeting (AGM) in Frankfurt am Main today.

“The successful implementation of #FutureFresenius means Fresenius is now simpler, more focused, stronger, and more resilient. We are now in a better position to anticipate change more quickly and, if necessary, respond more effectively,” said Michael Sen, CEO of Fresenius. “Fresenius is essential to healthcare systems around the world – through our hospitals and our products, without which patient care would not be possible.” Furthermore, the company’s “Local for Local” strategy, focused on local value creation, manufacturing, and jobs, also strengthens its resilience.

Fresenius began the year from a position of strength and launched the next phase of its #FutureFresenius strategy, Rejuvenate. Reducing the shares in Fresenius Medical Care in March this year was the first milestone. Fresenius used the proceeds to strengthen its balance sheet and further fuel innovation. Rejuvenate is about advancing and strengthening its core businesses. In addition, the company will scale up its three platforms – (Bio)Pharma, MedTech, and Care Provision – to unlock new long-term growth opportunities and achieve higher earnings.

In the 2024 financial year, Fresenius once again increased the pace of growth in revenue and earnings. “Last year, we not only kept our promises but even exceeded our expectations and raised our guidance twice,” said Sen. The company achieved this through its efforts, to which all operating businesses contributed. Productivity also increased, and the self-imposed target corridor for the leverage ratio was achieved for the first time in seven years. By 2024, Fresenius had reduced its net debt by 2 billion euros and achieved an operating cash flow of 2.4 billion euros. A dividend of 1.00 euro per share was proposed for the past financial year during the Annual General Meeting.

Fresenius also considers itself on track for 2025. “Our mission to save and improve human lives continues to drive us forward in the new financial year. With the next phase of #FutureFresenius, we want to continue our success story in 2025,” said Sen, referring to the strong start to the year. In early May, Fresenius confirmed its guidance for the full year 2025 following excellent growth in revenue and earnings during the first quarter.

The AGM will be held in person, with several hundred shareholders attending this year’s event at Messe Frankfurt.

* * *
The letter by Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius, and the speech by Michael Sen, Chief Executive Officer of Fresenius, can be downloaded here: Annual General Meeting | FSE

About Fresenius

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered n Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com
Follow us on social media: www.fresenius.com/socialmedia